| # | Drug | Count |
|---|---|---|
| 0 | DOXORUBICIN | 28 |
| 1 | DOXORUBICIN HYDROCHLORIDE | 23 |
| 2 | CYCLOPHOSPHAMIDE | 18 |
| 3 | CYCLOPHOSPHAMIDE FOR INJECTION | 18 |
| 4 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 18 |
| 5 | CISPLATIN | 7 |
| 6 | ETOPOSIDE | 5 |
| 7 | IFOSFAMIDE | 5 |
| 8 | IFOSFAMIDE FOR INJECTION | 5 |
| 9 | METHOTREXATE | 5 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | SOYBEAN OIL | 1 | 0.0015 |
| 1 | PENTOSTATIN | 1 | 0.0010 |
| 2 | DOXORUBICIN HYDROCHLORIDE | 23 | 0.0007 |
| 3 | RELUGOLIX, ESTRADIOL HEMIHYDRATE, AND NORETHINDRONE ACETATE | 1 | 0.0007 |
| 4 | FOLLITROPIN ALFA | 1 | 0.0005 |
| 5 | DOXORUBICIN | 28 | 0.0003 |
| 6 | ELAGOLIX | 1 | 0.0003 |
| 7 | GAUNFACINE | 1 | 0.0003 |
| 8 | IFOSFAMIDE FOR INJECTION | 5 | 0.0002 |
| 9 | PROGESTERONE | 5 | 0.0002 |
| # | Drug class | Count |
|---|---|---|
| 0 | Alkylating Drug [EPC] | 19 |
| 1 | Platinum-based Drug [EPC] | 7 |
| 2 | Folate Analog Metabolic Inhibitor [EPC] | 5 |
| 3 | Nucleoside Metabolic Inhibitor [EPC] | 5 |
| 4 | Progesterone [EPC] | 5 |
| 5 | Topoisomerase Inhibitor [EPC] | 5 |
| 6 | Calcineurin Inhibitor Immunosuppressant [EPC] | 2 |
| 7 | Estrogen [EPC] | 2 |
| 8 | Janus Kinase Inhibitor [EPC] | 2 |
| 9 | Progestin [EPC] | 2 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Lipid Emulsion [EPC] | 1 | 0.0004 |
| 1 | Progesterone [EPC] | 5 | 0.0002 |
| 2 | Alkylating Drug [EPC] | 19 | 0.0001 |
| 3 | RNA Synthetase Inhibitor Antibacterial [EPC] | 1 | 0.0001 |
| 4 | Topoisomerase Inhibitor [EPC] | 5 | 0.0001 |
| 5 | Recombinant Human Growth Hormone [EPC] | 1 | 0.0000 |
| 6 | Gonadotropin Releasing Hormone Receptor Antagonist [EPC] | 1 | 0.0000 |
| 7 | Provitamin D2 Compound [EPC] | 1 | 0.0000 |
| 8 | Platinum-based Drug [EPC] | 7 | 0.0000 |
| 9 | Central alpha-2 Adrenergic Agonist [EPC] | 1 | 0.0000 |